Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
Other Sizes |
|
Purity: ≥98%
(+)-JQ1 carboxylic acid is the free carboxylic acid (COOH) form of (+)-JQ1 (tert-Butyl ester form-COOtBu). (+)-JQ1 is a potent and highly specific BET (Bromodomain and extra terminal domain) bromodomain inhibitor, with IC50 of 77 nM and 33 nM for BRD4(1/2) in enzymatic assays. (−)-JQ1 shows no significant interaction with any bromodomain. Besides, (−)-JQ1 enantiomer is comparatively inactive in nuclear protein in testis (NUT) midline carcinoma (NMC). (+)-JQ1 has high specificity for BET in that it only binds to bromodomains of the BET family, but not to any bromodomains of non-BET family. (+)-JQ1 has potential antineoplastic activity against various cancers such as MM (Multiple myeloma), pancreatic ductal adenocarcinoma and ovarian cancer etc. Its mechanism of action is to inhibit c-MYC and upregulate p21. (+)-JQ1 has been used as a chemical probe to investigate the role of BET bromodomains in the transcriptional regulation of oncogenesis.
ln Vitro |
On the surface of B16F10 cells, JQ-1 carboxylic acid reduces the expression of PD-L1 [1].
|
||
---|---|---|---|
ln Vivo |
|
||
Animal Protocol |
|
||
References |
[1]. Huang Y, et, al. Design, Synthesis, and Evaluation of Trivalent PROTACs Having a Functionalization Site with Controlled Orientation. Bioconjug Chem. 2022 Jan 19;33(1):142-151.
[2]. Chen W, et, al. Dual drugs decorated bacteria irradiate deep hypoxic tumor and arouse strong immune responses. Biomaterials. 2022 Jul;286:121582. |
Molecular Formula |
C19H17CLN4O2S
|
|
---|---|---|
Molecular Weight |
400.88
|
|
CAS # |
202592-23-2
|
|
Related CAS # |
(+)-JQ-1;1268524-70-4;(R)-(-)-JQ1 Enantiomer;1268524-71-5
|
|
SMILES |
O=C(O)C[ C@H]1C2=NN=C(C)N2C3=C(C(C)=C(C)S3)C(C4=CC=C(Cl)C=C4)=N1
|
|
InChi Key |
LJOSBOOJFIRCSO-AWEZNQCLSA-N | |
Chemical Name |
|
|
Synonyms |
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.24 mM) (saturation unknown) in 5% DMSO + 40% PEG300 + 5% Tween80 + 50% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.24 mM) (saturation unknown) in 5% DMSO + 95% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1.39 mg/mL (3.47 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: ≥ 1.39 mg/mL (3.47 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 13.9 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 5: ≥ 1.39 mg/mL (3.47 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 13.9 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.4945 mL | 12.4726 mL | 24.9451 mL | |
5 mM | 0.4989 mL | 2.4945 mL | 4.9890 mL | |
10 mM | 0.2495 mL | 1.2473 mL | 2.4945 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Leukemia and lymphoma cell lines are broadly sensitive to BET-bromodomain inhibition.Proc Natl Acad Sci U S A.2011 Oct 4;108(40):16669-74. th> |
---|
Gene expression profiling of LP-1 and Raji cells treated with active or inactive BET inhibitors.Proc Natl Acad Sci U S A.2011 Oct 4;108(40):16669-74. td> |
Small molecule BET-bromodomain inhibition suppressesMYCtranscription.Proc Natl Acad Sci U S A.2011 Oct 4;108(40):16669-74. td> |
MYC reconstitution significantly protects cells from BET-mediated effects.Proc Natl Acad Sci U S A.2011 Oct 4;108(40):16669-74. th> |
---|
BET-bromodomain inhibition decreases tumor load in vivo.Proc Natl Acad Sci U S A.2011 Oct 4;108(40):16669-74. td> |
Integrated genomic rationale for BET bromodomains as therapeutic targets in MM.Cell.2011 Sep 16;146(6):904-17. td> |
Inhibition of Myc-dependent transcription by theJQ1BET bromodomain inhibitor.Cell.2011 Sep 16;146(6):904-17. th> |
---|
BET inhibition suppressesMYCtranscription in MM.Cell.2011 Sep 16;146(6):904-17. td> |
Regulation ofMYCtranscription by BET bromodomains.Cell.2011 Sep 16;146(6):904-17. td> |
Anti-myeloma activity ofJQ1in vitro.Cell.2011 Sep 16;146(6):904-17. th> |
---|
JQ1induces cell cycle arrest and cellular senescence in MM cells.Cell.2011 Sep 16;146(6):904-17. td> |
Translational implications of BET bromodomain inhibition in MM.Cell.2011 Sep 16;146(6):904-17. td> |